Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC7 | O00311 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802257 | 0.84 | CYP19A1 (0.52) | CDC7CDK2PARP1CYP2C19CYP19A1 | |
| SCHEMBL2295195 | 0.82 | CDC7 (0.53) | CDC7CDK2PARP1CYP2C19SLC22A12 | |
| SCHEMBL1150333 | 0.80 | CDC7 (0.54) | CDC7CDK2PARP1CYP2C19SLC22A12 | |
| SCHEMBL30828406 | 0.80 | CDC7 (0.54) | CDC7CDK2PARP1CYP2C19SLC22A12 | |
| SCHEMBL27839782 | 0.79 | BIRC5 (0.54) | CDC7CDK2PARP1CYP2C19CYP19A1 | |
| SCHEMBL7892111 | 0.79 | CDC7 (0.50) | CDC7CDK2PARP1CYP2C19SLC22A12 | |
| SCHEMBL20603929 | 0.79 | CDC7 (0.58) | CDC7CDK2PARP1CYP2C19SLC22A12 | |
| SCHEMBL28537449 | 0.79 | L3MBTL1 (0.54) | CDC7CDK2PARP1CYP2C19SLC22A12 | |
| SCHEMBL28547121 | 0.79 | CDC7 (0.50) | CDC7CDK2PARP1CYP2C19SLC22A12 | |
| SCHEMBL4804886 | 0.79 | CDC7 (0.42) | CDC7CDK2CYP2C19CYP19A1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER INC | 2008-04-17 | — | — | US | disclosed |
| WO-2008004117-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090834-A1 | SELECTIVE AZOLE PDE10A INHIBITOR COMPOUNDS | PDE5A, PDE3B, PDE12 | CDC7 1474/4885CDK2 2090/4885PARP1 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.